ALX ONCOLOGY HOLDINGS INC
Clinical-stage immuno-oncology company developing therapies to combat cancer.
ALXO | US
Overview
Corporate Details
- ISIN(s):
- US00166B1052
- LEI:
- Country:
- United States of America
- Address:
- 323 ALLERTON AVENUE, 94080 SOUTH SAN FRANCISCO
- Website:
- https://alxoncology.com/
- Sector:
- Manufacturing
Description
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies that enhance the immune system's ability to combat cancer. The company's lead therapeutic candidate, evorpacept, is a next-generation CD47 blocking agent designed to maximize clinical activity while minimizing inherent toxicities. Evorpacept is engineered to block the CD47 checkpoint pathway, a signal used by cancer cells to evade the immune system. The company is advancing a broad clinical development program for evorpacept in combination with other anti-cancer agents for the treatment of various hematologic malignancies and solid tumors. The strategic goal is to establish evorpacept as a cornerstone therapy that can be integrated with current and future standards of care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ALX ONCOLOGY HOLDINGS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALX ONCOLOGY HOLDINGS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALX ONCOLOGY HOLDINGS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
